FDA-submitted CBER IND 33055 | Phase IIb/III-ready clinical-development positioning | U.S., India, and UAE/Dubai regulatory expansion planning.

Duniya SanoStem Inc. is advancing SanoMSC, an allogeneic mesenchymal bone marrow cell therapy platform for ischemic stroke with persistent neurologic impairment. The company has submitted CBER IND 33055 through FDA ESG NextGen as eCTD sequence 0000 and is pursuing a formal FDA clinical-development pathway, including RMAT and Type B meeting engagement.

Investor / Partner Inquiries Clinical Trial Updates Contact Duniya SanoStem

Who We Are

Duniya SanoStem Inc. is a biotechnology company focused on cellular therapy development, regulatory submission strategy, and global clinical commercialization planning for serious neurologic conditions. The company is building its SanoMSC program around FDA-facing clinical development, manufacturing readiness, and international regulatory expansion.

Learn More

FDA-submitted CBER IND 33055 | Phase IIb/III-ready clinical-development positioning | U.S., India, and UAE/Dubai regulatory expansion planning.

Who We Are

Meet Our Team

Dr. Randeep S. Dhillon PHD

Dr. Duke Adams

Mr. Vishal Kumar

Mr. Gurjit S. Pandher

Featured Video

News & Events

Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke